Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc director and CEO Pablo G. Legorreta received 143,821 Class A Ordinary Shares as an equity award. The shares were granted at $0.00 per share in connection with the settlement of Equity Performance Awards and are described as an exempt acquisition under Rule 16b-3. Following this grant, Legorreta directly holds 1,240,604 Class A Ordinary Shares. He also has indirect holdings through family members and related entities, including 1,040,410 shares held by the Legorreta Children 2002 Trust and 901,590 shares held by the GST-Exempt Legorreta 2012 Family Trust. The filing does not show any open-market purchases or sales, indicating a routine compensation-related share award rather than a discretionary trade.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported an exempt acquisition of Class A Ordinary Shares through an affiliated entity. On May 6, 2026, TPC RP EPA1 LLC, an entity associated with him, received 24,263 Class A Ordinary Shares at $0.00 per share in connection with the settlement of Equity Performance Awards pursuant to Rule 16b-3.
Following this award, TPC RP EPA1 LLC held 64,399 Class A Ordinary Shares indirectly. Additional holdings reported as of the same date include 1,500 shares held directly, 1,450 held indirectly by spouse, 23,270 held indirectly by IRA, and 24,170 held indirectly by spouse’s IRA.
Royalty Pharma plc executive Christopher Hite reported an exempt equity award rather than an open-market trade. On May 6, 2026, an entity associated with him, SCH Investment Partners LLC, acquired 24,263 Class A Ordinary Shares at $0.00 per share in connection with the settlement of Equity Performance Awards, treated as exempt under Rule 16b-3. Following this award, SCH Investment Partners LLC held 709,399 Class A Ordinary Shares indirectly. A separate entry shows 70,000 Class A Ordinary Shares held directly as of the same date, recorded as a holding entry without a reported purchase or sale.
Urist Marshall reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc EVP Marshall Urist received a stock grant of 18,197 Class A Ordinary Shares on an exempt basis under Rule 16b-3, in connection with the settlement of Equity Performance Awards. The shares were awarded at no cash cost, increasing his direct holdings to 45,565 Class A Ordinary Shares, in addition to 19,020 shares held indirectly through an IRA.
Royalty Pharma plc reported higher first-quarter 2026 results, driven by growth in royalty income and strong cash generation. Total income and other revenues reached $630.6 million, up from $568.2 million a year earlier, and net income attributable to Royalty Pharma plc rose to $294.7 million from $239.3 million.
Basic and diluted earnings per Class A share were $0.67, compared with $0.55 in 2025. Operating cash flow was robust at $718.2 million, while the company recorded a $69.4 million non-cash impairment on its Tazverik royalty and recognized $122.3 million of share-based compensation following its 2025 internalization. Cash stood at $586.4 million and total debt principal at $9.18 billion as of March 31, 2026.
Royalty Pharma plc reported strong first-quarter 2026 results, with double-digit growth and higher full-year guidance. Portfolio Receipts rose 10% to $925 million, while Royalty Receipts grew 13% to $887 million, driven mainly by Tremfya, Voranigo and Evrysdi. Net cash provided by operating activities increased 20% to $718 million.
Adjusted EBITDA climbed 21% to $889 million and Portfolio Cash Flow rose 18% to $722 million, highlighting robust cash generation. The company raised 2026 Portfolio Receipts guidance to $3,325 million–$3,450 million, implying expected Royalty Receipts growth of 4%–8%. Royalty Pharma also executed $528 million of capital deployment, including three royalty acquisitions with up to $1.25 billion in announced value, paid a quarterly dividend of $0.235 per share and repurchased about 1.1 million shares.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported open-market sales of a total of 34,791 Class A Ordinary Shares on April 28, 2026. The shares were sold at a weighted average price of $49.7784 per share through entities TPC RP EPA1 LLC and TPC RP 2021, LLC, under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. Following the transactions, TPC RP EPA1 LLC held 40,136 Class A Ordinary Shares, while TPC RP 2021, LLC held none, and the filing also lists additional direct and IRA-related holdings for Coyne and his spouse.
RPRX affiliate(s) reported proposed and recent sales of Common Stock via Form 144. The notice lists multiple dispositions by entities including TPC RP EPA1 LLC and TPC RP 2021 LLC, showing individual sale dates, share counts (examples: 1,875 and 32,916), and corresponding proceeds.
Royalty Pharma plc highlights positive Phase 3 results from partner Revolution Medicines’ RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. The study met all primary and key secondary endpoints, including progression-free and overall survival, and Revolution Medicines plans to submit the data to global regulators, including a future U.S. FDA New Drug Application.
These results activate the second $250 million tranche under a previously announced $2 billion funding deal between the companies, bringing Royalty Pharma’s funding to $500 million so far. Royalty Pharma is now entitled to tiered royalties of 4.55% on daraxonrasib (and certain zoldonrasib sales), with potential step-ups to as high as 7.80% on lower sales tiers if Revolution Medicines draws the remaining synthetic royalty funding, alongside access to a senior secured term loan facility of up to $750 million linked to FDA approval and future sales milestones.